In turn, the administration of high doses of exogenous bioactive adropin to these mice caused ameliorated NASH progression, possibly through activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway (Chen et al., 2019). This evidence concerns the gene NFE2L2 and metabolic dysfunction-associated steatohepatitis.